Twelve patients with T cell large granular lymphocyte leukemia and associated hematocytopenia were treated in a phase I doseescalation trial with the murine monoclonal antibody Mik␤1. Mik␤1 identifies CD122, the ␤-subunit shared by the IL-2 and IL-15 receptors. At the doses administered in this study the antibody inhibited the actions of IL-15 on both natural killer and T cells and that of IL-2 when the intermediate-affinity IL-2 receptor was expressed. Mik␤1 treatment was not associated with significant toxicity or with the development of an immune response to the infused monoclonal antibody. At these doses of Mik␤1, >95% saturation of the IL-2͞IL-15␤ receptor (CD122) on the surfaces of the leukemic cells was achieved. Furthermore, in seven patients this led to the down-modulation of the receptor from the surfaces of the leukemic cells. Nevertheless, no patients manifested a reduction in peripheral leukemic cell count or an amelioration of their hematocytopenia. This latter observation may reflect the fact that the monoclonal T cell large granular lymphocyte leukemia leukemic cells of the patients did not produce IL-2 or IL-15 or require their actions for cell survival. In light of the lack of toxicity and lack of immunogenicity of the antibody observed in the present study and the role for IL-15 in the pathogenesis of autoimmune diseases, clinical trials should be performed using the humanized version of Mik␤1 in groups of patients with human T cell lymphotropic virus I-associated myelopathy͞tropical spastic paraparesis, rheumatoid arthritis, multiple sclerosis and refractory celiac disease.
IL-2͞IL-15␤ receptor (CD122) ͉ natural killer cells ͉ cytokine

I
nterleukin-15 is an inflammatory cytokine that stimulates T and natural killer (NK) cell activity and induces expression of TNF-␣, IL-1␤, and inflammatory chemokines (1) (2) (3) (4) . IL-15 inhibits the self-tolerance mediated by IL-2-induced activationinduced cell death (5) . In addition, IL-15 facilitates the survival of CD8
ϩ memory T cells, including self-directed memory cells (5-7). The heterotrimeric IL-15 receptor includes a private IL-15-specific receptor subunit, IL-15R␣, together with the IL-2͞IL-15R␤ subunit that is shared with IL-2 and the common ␥-chain receptor subunit that is also used by IL-2, IL-4, IL-7, IL-9, and IL-21 (3, 8) . In contrast to other interleukins, IL-15 acts as a membrane-associated cytokine. IL-15 and its private receptor subunit, IL-15R␣, are components of an immunological synapse that develops between antigen-presenting cells and effector NK and CD8 T cells (9, 10) . The expression of IL-15R␣ and associated IL-15 are coordinately induced on antigenpresenting cells through the stimulation of Toll-like and IFN receptors. IL-15 receptor and IL-15␣ form stable complexes on the cell surfaces of activated antigen-presenting cells. Upon cell-cell interaction these complexes on activated monocytes and dendritic cells present IL-15 in trans to resting NK and CD8 ϩ T cells that express only IL-2͞IL-15R␤ and the common ␥-chain but not IL-15R␣ (9) . Abnormalities of IL-15 expression have been described in patients with select lymphoid malignancies and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease, as well as in diseases associated with human T cell lymphotropic virus I (HTLV-I) (3, 8, (11) (12) (13) (14) (15) (16) .
A number of approaches have been developed to treat autoimmune diseases by blocking IL-15 action (8, (12) (13) (14) (15) (16) . Our efforts to inhibit the actions of IL-15 for the therapy of autoimmune diseases and HTLV-I-associated disorders have focused on the Mik␤1 monoclonal antibody that interacts with the IL-2͞IL-15R␤ (CD122) receptor subunit (17, 18) . We demonstrated that this monoclonal antibody prevents the transpresentation of IL-15 to NK and CD8 ϩ T cells and thereby inhibits IL-15-mediated effects (9, 18, 19) . In the present study we translate these observations concerning IL-15 blockade into clinical trials using the monoclonal antibody Mik␤1.
The present study was directed toward the evaluation of the safety and efficacy of the murine monoclonal antibody Mik␤1 in patients with T cell large granular lymphocyte leukemia (T-LGL) associated with hematocytopenia. The type of T-LGL that is the focus of the present study manifests the phenotype CD2 ϩ , CD3 ϩ , CD8 ϩ , CD57 ϩ , CD122 ϩ , CD4 Ϫ , and CD25 Ϫ (IL-2R␣) (20) (21) (22) (23) (24) (25) . After the addition of IL-2 or IL-15, the T-LGL cells develop lymphokine-activated killer activity. The majority of T-LGL leukemic cell populations, including all in the present study, were monoclonal as assessed by PCR or Southern blot analyses (26, 27) . In most cases, T-LGL follows a chronic course characterized by peripheral blood lymphocytosis, with splenic and bone marrow infiltration with leukemic cells that is associated with neutropenia and recurrent infections. Other clinical manifestations include pure red cell aplasia and thrombocytopenia. Autoimmune phenomena including hemolytic anemia as well as rheumatoid arthritis occur in a proportion of patients and contribute to morbidity and mortality (20, 21) .
The scientific basis for the present therapeutic study of Mik␤1 was that the monoclonal leukemic CD8
ϩ lymphocytes of patients with T-LGL express large numbers of the IL-2͞IL-15R␤ receptor subunit identified by Mik␤1 on their cell surfaces (21-23, 25, 28, 29) . Resting normal NK and T-LGL cells did not express the IL-2R␣ receptor subunit; however, it could be induced by the addition of IL-2 to these cells that express the ␤ and common ␥-receptor subunits, demonstrating that these receptors can signal in the initial absence of IL-2R␣ (30) . In subsequent studies it was shown that the IL-2 receptor ␤-chain plays a role in mediating signals for lymphokine-activated killer and NK cells in proliferation activities and that there is an induction of NK activity in LGL cells when they are activated by the anti-CD3 monoclonal antibody and by IL-2 that acts through the ␤-subunit (24) . In addition, LGL cells are stimulated by IL-15, and this cytokine mediates its activity through subunits of the IL-2 receptor. In subsequent studies, the IL-2͞IL-15R␤ subunit was shown to be a pivotal component of the heterotrimeric IL-15 receptor (1, 3, 19, 31) . Furthermore, Mik␤1 blocks IL-15 action on T and NK cells as well as T-LGL (1, 3, 32) .
In the present study, we confirmed that the Mik␤1 antibody blocks IL-15 action in NK and T cell lines. Furthermore, in IL-2R␣-nonexpressing cells such as T-LGL cells, Mik␤1 inhibited the action of IL-2 as well. The administration of the antibody in the clinical setting was associated with the modulation of the target antigen IL-2͞IL-15R␤ from the surfaces of the leukemic cells. The administration of Mik␤1 to the patients was not associated with significant toxicity, nor did it elicit an antibody response to the infused monoclonal antibody. However, the patients with T-LGL did not manifest a clinical response to a short course of murine Mik␤1.
Results
Preclinical Specificity of Mik␤1 for IL-2͞IL-15R␤ (CD122) and Reactivity
with Normal Human Tissues. The murine Mik␤1 antibody was the standard monoclonal antibody used in the International Leukocyte Differentiation Antigen Workshop that first defined CD122. In the present study Mik␤1 did not react with the unmodified 32D murine hematopoietic cell line lacking expression of human CD122, but it did bind to this cell line after transfection with an expression construct encoding human IL-2R͞IL-15R␤ (Fig. 3 , which is published as supporting information on the PNAS web site).
Distribution analyses to define the tissue targets of Mik␤1 antibody binding were performed on three sets of human tissue specimens obtained from autopsy by standard indirect immunofluorescence analyses. No binding of Mik␤1 was demonstrated to the following tissues: adrenal, bladder, bone marrow, brain, breast, sternum, cervix, esophagus, eye, heart, kidney, large intestine, liver, lung, lymph node, ovary, pancreas, parathyroid, parotid, pituitary, prostate, skin, small intestine, cervical cord, spleen, stomach, testis, thymus, thyroid, tonsils, or uterus. Three of three skeletal muscle specimens showed 1ϩ to 2ϩ reactivity. However, no RNA message encoding IL-2͞IL-15R␤ (CD122) could be demonstrated by Northern blot analysis in RNA-extracted skeletal muscle from a cynomolgus monkey. Mik␤1 reacted with Epstein-Barr-virustransformed B cell lines, phytohemagglutinin-activated lymphocytes, and the majority of NK cell lines. Thus, the epitope identified by Mik␤1 appears limited to expression in muscle cells, NK cells, T-LGL, and activated B and T lymphocytes.
Mik␤1 as an Inhibitor of IL-15-and IL-2-Induced Proliferation of
Cytokine-Dependent Cell Lines. To examine the specificity of the antibodies used in these studies, proliferation assays were performed with the cytokine-dependent 32D␤ and the Kit-225 T cell line (both IL-2-and IL-15-responsive). With the 32D␤ cell line that expresses only intermediate cytokine affinity, IL-2 and IL-15 receptors involving the common ␥-chain, and IL-2͞IL-15R␤ subunits, IL-2-mediated proliferation was inhibited by the addition of 10 g͞ml Mik␤1 (Fig. 1A) . Furthermore, IL-15-mediated proliferation of 32D␤ was inhibited by Mik␤1 (Fig.  1B) . The antibody did not inhibit the proliferation of 32D␤ mediated by IL-3 (data not shown). In the case of Kit-225, a cell line that expresses IL-2R␣ as well as IL-2͞IL-15R␤ and the common ␥-chain Mik␤1, did not inhibit IL-2-mediated proliferation in this IL-2 high-affinity IL-2R-expressing cell line, whereas anti-Tac blocked such IL-2-mediated proliferation ( Fig.  2A) . IL-15-induced proliferation of Kit-225 was inhibited by Mik␤1 but not by anti-Tac (Fig. 2B ). Thus, with the Kit-225 cell line each antibody blocked only the proliferation mediated by its cognate cytokine. These studies demonstrate the fidelity of each antibody and suggest that the proliferation inhibition observed is due to blockade of receptor for the targeted cytokine.
Mik␤1 Led to the Saturation of CD122 or Its Modulation from the Cell
Surface. The patients initially manifested strong expression of CD122 when assessed by analysis with Mik␤1 and with Mik␤3 that defines an epitope distinct from that identified by Mik␤1. The reactivity with fluorochrome-labeled Mik␤1 was virtually eliminated in the patients during the 48 h after infusion of 1.5 mg͞kg monoclonal antibody. The reactivity of Mik␤3 with the leukemic cells was not inhibited by the presence of nonfluorochrome-labeled Mik␤1 when the antibody was added in vitro immediately before the infusions. However, in 7 of the 12 patients who were reanalyzed 48 h after the administration of Mik␤1, there was a marked reduction in the reactivity using immunofluorescence analyses with both Mik␤1 and Mik␤3. Because there was no reduction in the number of leukemic cells as assessed by the CD2 ϩ , CD8 ϩ , CD57 ϩ phenotype analyses, the reduced reactivity did not reflect the elimination of the target cells. The reduction in reactivity with directly labeled murine Mik␤1 could theoretically have reflected saturation of the receptor with the infused monoclonal antibody. However, the loss of reactivity with Mik␤3 that was observed in seven patients cannot be explained by this mechanism. Rather, these losses of reactivity appear to reflect down-modulation of CD122 from the surface of the leukemic cells, possibly by monoclonal antibodymediated internalization of the receptor. This finding suggests that the maintenance of CD122 is not required for the survival of the T-LGL cells at least for the period involved in the present study. There was reexpression of IL-2͞IL-15R␤ with both Mik␤1 and Mik␤3 when assayed 4-6 weeks after the infusions.
Response and Toxicity to Murine Mik␤1 in Patients with T-LGL. All patients manifested stable disease. None developed a reduction in the peripheral leukemic count or an amelioration of their hematocytopenia.
No toxicity in terms of clinical hematological or clinical chemical analysis was observed after a single i.v. dose administration of 2.0 mg͞kg of a humanized Mik␤1 preparation to each of three cynomolgus monkeys in a formal toxicological analysis. In addition, no antibody-related abnormalities were observed in these animals at autopsies performed 43 days after the Mik␤1 administration. No serious adverse events were observed in any patient in the present trial as assessed by clinical evaluation or routine hematological and clinical chemistry tests. With the exception of grade 2 fever observed in two patients immediately after the monoclonal antibody administration and grade 2 elevation of bilirubin in one of these individuals, no other adverse events were observed.
Pharmacokinetics of Mik␤1. In preclinical studies, murine Mik␤1 and murine anti-Tac (anti-IL-2R␣, anti-CD25 antibody) were radiolabeled with 125 I and 131 I, respectively, and the mixture was administered to cynomolgus monkeys. The terminal half-life of decline from the serum of radiolabeled Mik␤1 was 36 h, and that of murine anti-Tac was 40 h.
In our clinical trial at the 1.5 mg͞kg dose in patients with T-LGL, Mik␤1 levels were quantitated in the serum in serial time points after the infusion of the antibody. The peak serum levels were 23-37 g͞ml, and the serum antibody concentration declined to a level of 8.9-11.6 g͞ml 48 h after the infusion and immediately before the next infusion.
Clinical Immunogenicity of Murine Mik␤1. The immunogenicity of murine Mik␤1 was assessed in cynomolgus monkeys and in patients by using a sensitive ELISA. Six animals undergoing a cardiac allograft received murine Mik␤1 at a dose of 1 mg͞kg every other day for 5 doses. None of the monkeys in the study developed antibodies to murine Mik␤1. In the human clinical trial murine Mik␤1 was administered i.v. on four occasions (days 1, 4, 7, and 10) to 12 patients with T-LGL. None of these 12 patients developed an antibody response to the infused murine Mik␤1 when assessed between days 6 and 10 and at 4-6 weeks after therapy. Thus, murine Mik␤1 does not appear to be a strongly immunogenic monoclonal antibody, and the lack of efficacy did not reflect the production by the patients of antibodies directed toward this murine monoclonal antibody. The expression of IL-2 and IL-15 mRNA was evaluated in the PBMC from 12 patients with T-LGL and 8 normal controls by using real-time PCR. Either no or only minimal IL-2 and IL-15 mRNA expression was observed in the patients examined. The mean mRNA expression for IL-15 for the patients was not different from that of normal control PBMC and was Ͻ10% of that of the positive control cell line HUT-102. Furthermore, the IL-2 mRNA expression was comparable to normal PBMC and was Ͻ5% of normal PBMC stimulated with ionomycin͞PMA. Furthermore, little or no secreted IL-2 and IL-15 was detected by ELISA performed on the 6-day culture supernatants of the PBMC of the six patients with T-LGL studied. In addition, these supernatants did not stimulate the proliferation of the IL-2-and IL-15-responsive cytokine-dependent cell line NK-92. Taken as a whole these studies suggest that the monoclonal T-LGL leukemic cells of the patients examined were not in an autocrine IL-2-or IL-15-mediated self-stimulatory phase, nor were they actively responding to IL-2 or IL-15 produced by the patients' nonleukemic cells. Thus, the patients with T-LGL did not fulfill the basic premise of the study that demanded that there was IL-2-or IL-15-induced proliferation of leukemic LGL that in turn could be inhibited by the administration of an anti-IL-2͞IL-15R␤-directed monoclonal antibody.
Discussion
We evaluated the toxicity, pharmacokinetics, and activity of the murine monoclonal antibody Mik␤1 directed toward IL-2͞IL-15R␤ (CD122) in patients with CD122-expressing T-LGL with hematocytopenia. No dose-limiting toxicity beyond a common toxicity criteria grade 2 increase in serum bilirubin in one case and grade 2 fever in two patients was observed after four administrations of Mik␤1 up to a dose of 1.5 mg͞kg. Furthermore, the murine monoclonal antibody did not elicit an immune response. On the basis of the pharmacokinetic and pharmacodynamic studies, the 1.5 mg͞kg dose was sufficient to maintain unbound antibody in the circulation until the subsequent administration of the antibody on this 1-, 4-, 7-, and 10-day schedule. Furthermore, it was sufficient to saturate and͞or modulate the CD122 receptor from the leukemic cell surfaces. The murine Mik␤1 was specific for the IL-2͞IL-15R␤ receptor in that it blocked the proliferative effect of IL-15 when assessed using cytokine-dependent T and NK cell lines. The antibody did not provide effective blockade of IL-2 when the highaffinity heterotrimeric IL-2 receptor was expressed. However, the antibody blocked the action of IL-2 in cells such as T-LGL cells that express the intermediate-affinity IL-2 receptor that does not include IL-2R␣ but involves only the IL-2͞IL-15R␤ receptor subunit and the common ␥-subunit. The T cells of the three T-LGL patients studied manifested ex vivo proliferation in response to 5,000 pg of IL-2 and to 20,000 pg of IL-15. These cytokine-induced prolifera-tions were abrogated by the addition of 10 g͞ml Mik␤1 to the cultures.
Despite its capacity to block IL-2-and IL-15-induced stimulation of IL-2͞IL-15␤-expressing and common ␥-chainexpressing T-LGL cells, no therapeutic efficacy was observed after administration of four doses of murine Mik␤1 over a 10-day period. A number of factors may underlie this lack of efficacy. One potential factor is that the time period of blockade of the IL-2͞IL-15 receptor achieved (10-12 days) may not be sufficient for effective action. In support of this possibility is the observation that, even in patients who ultimately responded favorably to cyclosporin A administration, a period of Ϸ3 months of therapy may be required for the initial response. A second factor is that use of murine Mik␤1 does not fix complement and does not manifest antibody-dependent cellular cytotoxicity with human mononuclear cells (18) . To address these issues of pharmacokinetics and function, a humanized form of Mik␤1 was generated that manifests antibody-dependent cellular cytotoxicity with human mononuclear cells (18) . An additional advantage in the use of humanized as opposed to murine Mik␤1 is in the pharmacokinetics of the antibodies. Murine Mik␤1 in cynomolgus monkeys had a terminal t 1/2 of survival in the serum of 36 h as compared with 96 h with the humanized version. These differences parallel those with anti-Tac (anti-IL-2R␣, CD25) where the murine version had a terminal t 1/2 of 40 h and the humanized version had a terminal t 1/2 of 103 h in cynomolgus monkeys. In studies in humans, humanized anti-Tac manifested a terminal t 1/2 in its serum die-away curve of 21 days (34). We hope that a comparable prolongation of survival of the humanized version of the Mik␤1 monoclonal antibody will be observed in humans. This prolonged action may maintain the long-term saturation of the CD122 receptor that may be required for effective therapy in T-LGL. These characteristics manifested by humanized Mik␤1, but not the murine form, were associated with greater efficacy in inhibiting cardiac allograft rejection in a cynomolgus monkey model. In particular, the humanized but not the murine version of Mik␤1 was effective in prolonging cardiac allograft survival in cynomolgus monkeys (19) .
A dominant factor that may underlie the lack of efficacy of this therapeutic modality in patients with LGL is that the basic premise of the study was not fulfilled by the monoclonal T-LGL cells studied. The premise was that IL-2 and IL-15 are required for the survival and function of the T-LGL cells and that Mik␤1 would block the interactions of IL-2 and IL-15 with the IL-2͞ IL-15R␤ receptor. However, in the present study the cells examined during the monoclonal leukemic phase of the disease did not appear to produce or require IL-2 or IL-15 for their survival. In particular, the T-LGL cells did not manifest ex vivo spontaneous proliferation, a hallmark of leukemic cells that are in a cytokine-mediated autocrine phase of the disease. Furthermore, the leukemic cells did not produce biologically meaningful quantities of mRNA encoding IL-2 or IL-15, nor did they secrete these cytokines into the media during ex vivo cultures. Thus, to be effective in patients in the noncytokine-dependent phase of T-LGL, the anti-CD122 antibody would have to have manifest cytotoxic activity. This requirement is not met by murine Mik␤1; however, it is a characteristic of humanized Mik␤1 that manifests antibody-dependent cellular cytotoxicity (18) .
Potentially more favorable targets for the action of Mik␤1, especially its humanized version, would be in the therapy of autoimmune diseases wherein disorders of IL-15 action have been reported and where it has been suggested that the interaction of IL-15 with its receptor subunits plays a pivotal role in the generation and maintenance of the autoimmune disorder (8, (11) (12) (13) (14) (15) (16) . For example, excessive IL-15 action has been demonstrated in patients with rheumatoid arthritis and has been proposed to be a required element in the pathogenesis of rheumatoid arthritis, inflammatory bowel disease, celiac disease, psoriasis, and multiple sclerosis (4, 8, 11-16, 35, 36) . Furthermore, diseases casually associated with infection with the retrovirus HTLV-I overexpress IL-15 and its receptor (14) . Ex vivo studies of PBMC from these patients suggest that the blockade of IL-2 and IL-15 actions by human Mik␤1 may be effective. For example, the spontaneous ex vivo proliferation of PBMC from patients with HTLV-I-associated myelopathy͞tropical spastic paraparesis was inhibited, in part, by human Mik␤1 (14) . Furthermore, by using tetramer technology, the addition of Mik␤1 to cells cultured ex vivo for 6 days from HTLV-I-associated myelopathy͞tropical spastic paraparesis patients led to a decline in the persistence of tax antigen-specific CD8 ϩ cells, which have been suggested to play a role in the damage to the central nervous system (14) .
Abnormalities of IL-15 have also been reported in association with the development and progression of rheumatoid arthritis. McInnes et al. (11) reported elevated levels of IL-15 in this disease. Furthermore, they demonstrated that IL-15 induced TNF-␣ in select circumstances and suggested that IL-15 may precede TNF-␣ in the cytokine cascade (11) . TNF-␣-directed therapy has proven to be of value in the treatment of patients with refractory rheumatoid arthritis (37) . However, such therapy directed toward TNF-␣ has the limitation that TNF-␣ does not act on memory CD8 T cells that may be directed toward normal host tissues. An advantage of IL-15-receptor-directed rather than TNF-␣-directed therapy would be that administration of a monoclonal antibody targeting IL-15 or its receptor not only might yield antiinflammatory effects but might also terminate the IL-15-mediated persistence of CD8 memory cells, including those directed toward host tissues. In light of the lack of toxicity and lack of immunogenicity of the antibody observed in the present study and the role for IL-15 in the pathogenesis of autoimmune diseases, clinical trials are needed using the humanized version of Mik␤1 in groups of patients with HTLV-Iassociated myelopathy͞tropical spastic paraparesis, rheumatoid arthritis, multiple sclerosis, and refractory celiac disease.
Materials and Methods
Patient Population. The eligibility requirements were as follows: (i) histologically confirmed T-LGL; (ii) clinically significant hematocytopenia defined as an absolute granulocyte count of Ͻ1,000 per mm 3 , a hemoglobin count of Ͻ8.0 g͞dl, or a platelet count of Ͻ50,000 per mm 3 ; (iii) circulating mononuclear cells that contain a monoclonal T cell population as demonstrated by Southern blot or PCR analysis of T cell antigen receptor ␤-chain gene rearrangement; and (iv) a leukemic cell phenotype of CD3 ϩ , CD8 ϩ , CD122 ϩ (IL-2͞IL-15R␤), and CD4 Ϫ . Patients with or without previous chemotherapy were eligible for inclusion in the study.
Twelve patients (median age, 57 years; range, 22-77 years; see Table 1 ) were treated. The patients' white blood cell count ranged from 1,760 to 15,700 per mm 3 (geometric mean, 4,994), and the lymphocyte counts ranged from 1,152 to 13,172 per mm 3 . The neutrophil count ranged from 0 to 1,710 per mm 3 . The number of leukemic cells characterized as CD8 ϩ , CD122 ϩ ranged from 632 to 12,408 per mm 3 (geometric mean, 3,071) ( Table 2 ). The phenotype was CD2 ϩ , CD3
ϩ , CD7 ϩ (11 of 12 patients), CD4 Ϫ , CD8
ϩ , CD122 ϩ , CD57 ϩ (11 of 12 patients), HLA-DR ϩ (8 of 10 patients). The CD4:CD8 ratio ranged from 0.06 to 0.38 (geometric mean, 0.19). The cells of eight of the patients were CD16 ϩ , and the cells of one of the patients were CD56 ϩ . The circulating mononuclear cells of all of the patients showed high-level expression of the CD122 (IL-2͞IL-15R␤), the target of the Mik␤1 monoclonal antibody.
Treatment Plan. Patients with T-LGL were entered at three sequential dose levels of administered Mik␤1. Four patients in group 1 received 0.5 mg͞kg. Three patients in group 2 received 1.0 mg͞kg, whereas five patients in group 3 received 1.5 mg͞kg i.v. on days 1, 4, 7, and 10. Adverse events were assessed by using the National Cancer Institute common toxicity criteria. The protocol was approved by the National Cancer Institute's Institutional Review Board, and the patients gave informed consent.
Monoclonal Antibody Production. The production and characterization of murine Mik␤1 were described in ref. 18 .
Functional Assay of Mik␤1 as an Inhibitor of IL-15-and IL-2-Induced
Proliferation of a Cytokine-Dependent Cell Line. To examine the specificity of the antibodies used in these studies, proliferation assays were performed with the cytokine-dependent cell lines 32D␤ and Kit-225, which were both IL-2-and IL-15-responsive (1, 32) . Cells were seeded for tissue culture with no cytokine or with exogenous IL-2 (a gift from Hoffmann-La Roche) or IL-15 (PeproTech, Rocky Hill, NJ). The concentration of IL-2 used with 32D␤ that does not express IL-2R␣ was 1 ng͞ml, whereas that for Kit-225 that expresses the high-affinity IL-2 receptor was 500 pg͞ml. The concentration of IL-15 used with the 32D␤ cell line was 20 ng͞ml, and that for Kit-225 was 3.0 ng͞ml. 
